secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001193125-26-206395
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools Q1 revenue $21.1M, up 5% YoY; operating loss cut 54%
----------------------------------------------------------------------

- Net loss from continuing ops $14.6M vs $23.4M YoY; adjusted EBITDA loss $3.1M, 78% improvement.
- Revenue $21.1M (+5% YoY); consumables up 35% to $11.0M, instruments down 33% to $4.5M.
- Cash & investments $524M at quarter end, plus $25M earnout received post-Q1; total ~$550M.
- Full-year 2026 revenue outlook unchanged at $80M-$85M; path to positive adjusted EBITDA exiting 2026.
- Operating expenses down 37% to $23.8M, helped by restructuring; non-GAAP gross margin 57.7%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000119312526206395/0001193125-26-206395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000119312526206395/lab-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-206395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer